Repros (RPRX) Up 2%+ Following 'Statistically Significant' Androxal Data
Tweet
Share
E-mailGet Alerts RPRX Hot Sheet
Join SI Premium – FREE
Repros Therapeutics Inc. (Nasdaq: RPRX) shares up 2.6 percent in late Thursday trading after reporting that Androxal achieved statistically significant versus a placebo in ZA-203 Phase 2b clinical study of Androxal in secondary hypogonadal men with moderate to severe dysfunction.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- MetaVia completes dose titration in Phase 1 Part 3 obesity trial
- Century Therapeutics to present CNTY-813 preclinical data at two fall congresses
- Forte Biosciences FB102 shows vitiligo improvement in phase 1b trial
Create E-mail Alert Related Categories
FDA, Insiders' BlogSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
